Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site


Lavinia Spain


Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268


L. Spain1, L. Gallegos2, Z. Tippu1, S. Hill2, K. Litchfield3, L. Au1, A. Gilchrist4, V. Primus4, A. Barhoumi2, S. Stanislaw2, S. Agrawal1, N. Shaikh1, N. Patel4, M. Mendoza2, G. Noel-Storr4, J.M.G. Larkin5, N. Alexander2, S. Turajlic3

Author affiliations

  • 1 Skin & Renal Unit, Royal Marsden NHS Foundation Trust, SW3 6JJ - London/GB
  • 2 Roche Tissue Diagnostics, Roche, 85755 - Tuscon/US
  • 3 Swanton Lab, The Francis Crick Institute, NW1 1AT - London/GB
  • 4 Histopathology, Royal Marsden NHS Foundation Trust, SW3 6JJ - London/GB
  • 5 Medicine, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3021


Intratumour heterogeneity is recognised across different tumour types and has implications for therapeutic resistance. At present, clinical practice often relies upon molecular information derived from a single biopsy of a primary or metastatic tumour. This information guides treatment choice but may not be representative of the diversity of the tumour. It is currently difficult to evaluate how effectively a single region guides treatment decisions because the formalin-fixed residual surgical sample that is not paraffin embedded for diagnostic purposes is typically thrown away. Retention and homogenisation – ‘blending’- of this residual formalin-fixed leftover tumour tissue creates a more representative sample for analysis. DNA may be extracted from this sample for sequencing. Pilot data in kidney cancer has demonstrated the potential of this methodology for robust mutational calling, accurate determination of cancer cell fraction and the ability to discern clonal from subclonal variants. Such information may be clinically relevant; for example, discerning resistant subclones prior to treatment, or identifying clonal neoantigens worth targeting with immunotherapy.

Trial design

In order to establish the feasibility of homogenization as a potential companion diagnostic tool, our study aims to 1) identify the proportion of primary tumour cases that have left over tissue amenable to homogenization across multiple tumour types and 2) pilot homogenization across multiple tumour types. The molecular profile of the homogenate will be compared to that obtained from the diagnostic specimen using next generation sequencing techniques. This is a prospective non-interventional study (NCT03832062). Patients undergoing surgical intervention at The Royal Marsden Hospital (NHS Foundation Trust) with leftover tumour tissue from primary breast, colorectal, gastric, pancreatic, ovarian, renal cancer and sarcoma surgeries, as well as melanoma lymph node dissections will be included in the feasibility assessment. We plan to homogenise 500 cases across different tumour types. The study opened in September 2018 and is expected to run for 2 years.

Clinical trial identification

NCT03832062; Release date: February 2019.

Editorial acknowledgement

Legal entity responsible for the study

Royal Marsden NHS Foundation Trust.


Ventana Medical Systems (a subsidiary of Roche).


L. Gallegos: Full / Part-time employment: Roche. S. Hill: Full / Part-time employment: Roche. A. Barhoumi: Full / Part-time employment: Roche. S. Stanislaw: Full / Part-time employment: Roche. M. Mendoza: Full / Part-time employment: Roche. J.M.G. Larkin: Research grant / Funding (institution): Roche; Advisory / Consultancy: Roche. N. Alexander: Full / Part-time employment: Roche; Shareholder / Stockholder / Stock options: Roche. S. Turajlic: Research grant / Funding (institution): Ventana Medical Systems (subsidiary of Roche). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.